| [1] |
Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines[J]. J Intensive Care, 2014, 2 (1): 15.
|
| [2] |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 801-810.
|
| [3] |
Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan[J]. Int J Hematol, 2016, 103 (3): 253-261.
|
| [4] |
Iba T, Yamada A, Hashiguchi N, et al. New therape-utic options for patients with sepsis and disseminated intravascular coagulation[J]. Pol Arch Med Wewn, 2014, 124 (6): 321-328.
|
| [5] |
中华医学会急诊医学分会，王力军，柴艳芬.脓毒症并发弥散性血管内凝血诊治急诊专家共识[J].中华危重病急救医学，2017，29（7）：577-580.
|
| [6] |
Okamoto K, Tamura T, Sawatsubashi Y. Sepsis and disseminated intravascular coagulation[J]. J Intensive Care, 2016 (4): 23.
|
| [7] |
Levi M, van der Poll T. Coagulation and sepsis[J]. Thromb Res, 2017 (149): 38-44.
|
| [8] |
Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan[J]. J Thromb Haemost, 2014, 12 (7): 1010-1019.
|
| [9] |
Wada H, Matsumoto T, Aota T, et al. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials: comment[J]. J Thromb Haemost, 2016, 14 (11): 2308-2309.
|
| [10] |
Hayakawa M, Kudo D, Saito S, et al. Antithrombin supplementation and mortality in sepsis-induced disseminated intravascular coagulation: a multicenter retrospective observational study[J]. Shock, 2016, 46 (6): 623-631.
|
| [11] |
Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation[J]. J Thromb Haemost, 2006, 4 (1): 90-97.
|
| [12] |
Iba T, Saitoh D, Wada H, et al. Efficacy and bleed-ing risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey[J]. Crit Care, 2014, 18 (5): 497.
|
| [13] |
Tagami T, Matsui H, Fushimi K, et al. Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis[J]. Thromb Haemost, 2015, 114 (3): 537-545.
|
| [14] |
Allingstrup M, Wetterslev J, Ravn FB, et al. Antithr-ombin Ⅲ for critically ill patients: a systematic review with meta-analysis and trial sequential analysis[J]. Intensive Care Med, 2016, 42 (4): 505-520.
|
| [15] |
Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis[J]. Crit Care, 2013, 17 (6): R297.
|
| [16] |
Murata A, Okamoto K, Mayumi T, et al. Recent change in treatment of disseminated intravascular coagulation in Japan: an epidemiological study based on a national administrative database[J]. Clin Appl Thromb Hemost, 2016, 22 (1): 21-27.
|
| [17] |
Hayakawa M, Yamakawa K, Saito S, et al. Recombin-ant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study[J]. Thromb Haemost, 2016, 115 (6): 1157-1166.
|
| [18] |
Eguchi Y, Gando S, Ishikura H, et al. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation[J]. J Intensive Care, 2014, 2 (1): 30.
|
| [19] |
高洁，靳英辉，吴荷宁，等.脓毒症相关弥漫性血管内凝血患者使用重组人可溶性血栓调节蛋白疗效的Meta分析[J/CD].中华危重症医学杂志（电子版），2015，8（6）：361-365.
|
| [20] |
Yoshimura J, Yamakawa K, Ogura H, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis[J]. Crit Care, 2015 (19): 78.
|
| [21] |
Itoh S, Shirabe K, Kohnoe S, et al. Impact of recombinant human soluble thrombomodulin for disseminated intravascular coagulation[J]. Anticancer Res, 2016, 36 (5): 2493-2496.
|
| [22] |
Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase Ⅲ, randomized, double-blind clinical trial[J]. J Thromb Haemost, 2007, 5 (1): 31-41.
|
| [23] |
Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis[J]. J Thromb Haemost, 2015, 13 (4): 508-519.
|
| [24] |
Vincent JL, Ramesh MK, Ernest D, et al. A random-ized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation[J]. Crit Care Med, 2013, 41 (9): 2069-2079.
|
| [25] |
Hagiwara A, Tanaka N, Uemura T, et al. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial[J]. BMJ Open, 2016, 6 (12): e012850.
|
| [26] |
Zhang C, Wang H, Yang H, et al. Recombinant hum-an soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis[J]. Am J Emerg Med, 2016, 34 (9): 1876-1882.
|
| [27] |
Tagami T, Matsui H, Fushimi K, et al. Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation[J]. Front Med (Lausanne), 2015 (2): 7.
|
| [28] |
Tagami T, Matsui H, Horiguchi H, et al. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study[J]. J Thromb Haemost, 2015, 13 (1): 31-40.
|
| [29] |
Murata A, Okamoto K, Mayumi T, et al. Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation[J]. Int J Clin Pharm, 2015, 37 (1): 139-147.
|
| [30] |
Iba T, Gando S, Saitoh D, et al. Efficacy and bleed-ing risk of antithrombin supplementation in patients with septic disseminated intravascular coagulation: a third survey[J]. Clin Appl Thromb Hemost, 2017, 23 (5): 422-428.
|
| [31] |
Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study[J]. Crit Care Med, 2001, 29 (11): 2081-2089.
|
| [32] |
Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial[J]. JAMA, 2003, 290 (2): 238-247.
|
| [33] |
Wunderink RG, Laterre PF, Francois B, et al. Recom-binant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial[J]. Am J Respir Crit Care Med, 2011, 183 (11): 1561-1568.
|
| [34] |
Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis[J]. Crit Care Med, 2015, 43 (3): 511-518.
|
| [35] |
Liu XL, Wang XZ, Liu XX, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study[J]. Exp Ther Med, 2014, 7 (3): 604-608.
|
| [36] |
Sakuragawa N, Hasegawa H, Maki M, et al. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)-a multicenter co-operative double-blind trial in comparison with heparin[J]. Thromb Res, 1993, 72 (6): 475-500.
|
| [37] |
周袁申，陈昱志，李婷，等.参麦注射液对气阴两虚型血瘀证脓毒症患者凝血功能的影响[J].中国中西医结合急救杂志，2016，23（3）：240-244.
|
| [38] |
Wang L, Liu Z, Dong Z, et al. Effects of Xuebijing injection on microcirculation in septic shock[J]. J Surg Res, 2016, 202 (1): 147-154.
|
| [39] |
张平平，王庆树，李志军，等.血必净注射液对脓毒症患者凝血功能的影响[J].中国中西医结合急救杂志，2014，21（3）：198-200.
|
| [40] |
Yin Q, Li C. Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation[J]. Evid Based Complement Alternat Med, 2014 (7): 949254.
|